Compare iShares Self-Driving EV and Tech (IDRV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Novo Nordisk A/S — how do they compare? iShares Self-Driving EV and Tech trades at $33.34 (market cap $264.50M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 625× iShares Self-Driving EV and Tech's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Novo Nordisk A/S for 116 Days on average.
| IDRV | NVO | |
|---|---|---|
Market Cap | $264.50M | $165.31B |
Volume | 48,021 | 11,432,838 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $63.98 |
52-Week Low | $32.68 | $35.29 |
Typical Hold Time | 73 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $33.34, down slightly (-0.06%) with a bearish technical signal. Moving averages indicate selling pressure while oscillators remain neutral. The stock faces resistance at $34 and support at $33. Recent news highlights mixed EV market conditions with strong European demand but weaker US adoption following subsidy changes. Chinese competition and regulatory uncertainties create headwinds for the sector.
The outlook remains cautious given technical weakness and sector challenges. Investment opportunity exists in global EV growth trends, particularly in Europe and China. Key risks include US regulatory uncertainty, Chinese market access restrictions, and volatile oil prices affecting consumer EV adoption decisions.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
